NVO Novo Nordisk A/S

-0.11  -0%
Previous Close 51.29
Open 51.22
Price To Book 16.84
Market Cap 121,538,878,801
Shares 2,374,733,857
Volume 1,089,470
Short Ratio 1.98
Av. Daily Volume 1,426,218

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced March 20, 2019. Estimated PDUFA date September 20, 2019 assuming 6-month priority review.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 trial to be initiated 3Q 2019.
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial to be initiated 2Q 2019.
Growth Hormone Deficiency (GHD)
Phase 2 data due 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
Hemophilia A
Phase 2 data due 4Q 2019.
Type 2 diabetes
Phase 2 trial initiated 1Q 2019.

Latest News

  1. The 10 Biggest Biotech Stocks
  2. Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
  3. Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
  4. Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
  5. NVS or NVO: Which Is the Better Value Stock Right Now?
  6. Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
  7. The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
  8. Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
  9. FDA approves non-insulin Type 2 diabetes drug for kids, the first to hit market in 20 years
  10. Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
  11. Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
  12. Jim Cramer: A Tale of Two Stocks
  13. Why This Dow Jones Pharmaceutical Giant Is Trying To Break Out
  14. What Should Investors Know About Novo Nordisk A/S's (CPH:NOVO B) Growth?
  15. This Pharma Wants To Scoop Its Rivals With An Oral Diabetes Med
  16. CORRECTED-Oral Novo Nordisk diabetes drug poses no more heart risk than placebo -study
  17. UPDATE 2-China stimulus, German rally help European stock end higher
  18. Eli Lilly Stock Is Falling and Novo Nordisk Is Rising on Diabetes-Drug Results
  19. BMY or NVO: Which Is the Better Value Stock Right Now?
  20. Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum